Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2018

Jan 22, 2019

SELL
$6.3 - $10.44 $18,900 - $31,320
-3,000 Closed
0 $0
Q3 2018

Oct 29, 2018

BUY
$6.82 - $11.26 $3,410 - $5,630
500 Added 20.0%
3,000 $30,000
Q2 2018

Jul 18, 2018

BUY
$5.99 - $9.1 $14,975 - $22,750
2,500 New
2,500 $16,000

Others Institutions Holding PTGX

About Protagonist Therapeutics, Inc


  • Ticker PTGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,084,100
  • Market Cap $2.04B
  • Description
  • Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...
More about PTGX
Track This Portfolio

Track Fny Investment Advisers, LLC Portfolio

Follow Fny Investment Advisers, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fny Investment Advisers, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fny Investment Advisers, LLC with notifications on news.